BEGIN:VCALENDAR VERSION:2.0 PRODID:-//BioCT - ECPv6.3.3.1//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:BioCT X-ORIGINAL-URL:https://bioct.org X-WR-CALDESC:Events for BioCT REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/New_York BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20210314T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20211107T060000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/New_York:20210505T090000 DTEND;TZID=America/New_York:20210505T113000 DTSTAMP:20240328T074500 CREATED:20210503T195617Z LAST-MODIFIED:20210503T195754Z UID:4680-1620205200-1620214200@bioct.org SUMMARY:Advances in Drug Discovery: From Human Genetic Signatures to Drug Targets - Hosted by JLabs DESCRIPTION:Johnson & Johnson Innovation will host a virtual scientific and partnering event on state-of-the-art developments in translational sciences\, bringing together entrepreneurs\, start-ups\, researchers\, and scientists from across Europe\, the US\, and beyond. \nEffective and robust human healthcare solutions are embedded in our collective and individual genetic make-up. Using large datasets such as the UK Biobank Whole Genome Sequencing programme we are increasingly able to identify genetic signatures relating to disease states (source). However\, this association is only the start of the journey. We need to drill down from these genetic and phenotypic associations to identify the function of those genes and then to the products of those genes which are causal for disease. Translating these human genetic signatures to causal inference underpins research activities across the life sciences industry. \nJohnson & Johnson Innovation\, in collaboration with Janssen Research & Development\, is seeking to gather entrepreneurs\, biotechs and academic researchers who seek solutions to these questions for a discussion on harnessing the next wave of science and innovation in translating human genetic signatures. \n\n\n\n\n\n\n\n\n\n\n\n\nAgenda \n\n\n\n\n\n\n\n\n\n\n09:00 ET Advances in Drug Discovery: From Human Genetic Signatures to Drug Targets \nGuna Rajagopal | Global Head Computational Sciences\, Janssen Research & Development \n\n\n\n\n\n\n\n\n\n\n09:20 ET Audience Q&A \n\n\n\n\n\n\n\n\n\n\n09:30 ET The Johnson & Johnson Innovation Co-Creation Model \nNerida Scott | Head of Johnson & Johnson Innovation EMEA \nElena Fernandez-Kleinlein | Head of JLABS EMEA\, Johnson & Johnson Innovation \n\n\n\n\n\n\n09:45 ET Audience Q&A \n\n\n\n\n\n\n09:50 ET Showcasing 4 Translational Genomics Innovators (5-min quick pitches) \nEnvisagenics | Maria Luisa Pineda \nNucleome Therapeutics | Danuta Jeziorska \nEnhanc3D Genomics | Debora Lucarelli \nMEDIC Life Sciences | Kyuho Han \n\n\n\n\n\n\n\n\n\n\n10:10 ET Q&A with the innovators \n\n\n\n\n\n\n\n\n\n\n10:15 ET Panel Discussion: Translating Human Genetic Data into Validated Targets \nLitao Zhang | Global Head of Discovery Technology and Molecular Pharmacology\, Discovery Science\, Janssen R&D \nCecilia Lindgren | Director at The Big Data Institute\, University of Oxford \nJaya Krishnan | CSO\, Genome Biologics \nAlex Aravanis | Senior Vice President & Chief Technology Officer\, Illumina \nTrevor Howe | Janssen Fellow\, Director and Head of Translational Genomics for Johnson & Johnson Innovation (Moderator) \n\n\n\n\n\n\n\n\n\n\n10:50 ET Audience Q&A \n\n\n\n\n\n\n\n\n\n\n\n11:00 ET Event close URL:https://bioct.org/event/advances-in-drug-discovery-from-human-genetic-signatures-to-drug-targets-hosted-by-jlabs/ END:VEVENT END:VCALENDAR